Immix Biopharma, Inc.
IMMX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $4,584 | $3,972 | $1,975 | $1,374 |
| G&A Expenses | $3,078 | $2,745 | $2,708 | $3,613 |
| SG&A Expenses | $3,078 | $2,745 | $2,708 | $3,613 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $7,663 | $6,718 | $4,683 | $4,987 |
| Operating Income | -$7,663 | -$6,718 | -$4,683 | -$4,987 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $85 | $104 | $150 | $186 |
| Pre-Tax Income | -$7,578 | -$6,614 | -$4,533 | -$4,801 |
| Tax Expense | $8 | $9 | $10 | $11 |
| Net Income | -$7,586 | -$6,623 | -$4,543 | -$4,812 |
| % Margin | – | – | – | – |
| EPS | -0.24 | -0.22 | -0.15 | -0.17 |
| % Growth | -9.1% | -46.7% | 11.8% | – |
| EPS Diluted | -0.24 | -0.22 | -0.15 | -0.17 |
| Weighted Avg Shares Out | 31,927 | 29,984 | 29,701 | 27,540 |
| Weighted Avg Shares Out Dil | 31,927 | 29,984 | 29,701 | 27,540 |
| Supplemental Information | – | – | – | – |
| Interest Income | $85 | $104 | $150 | $186 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $97 | $80 | $59 | $41 |
| EBITDA | -$7,481 | -$6,638 | -$4,624 | -$4,946 |
| % Margin | – | – | – | – |